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ORIGINAL ARTICLE
Oxytocin efﬁcacy is modulated by dosage and oxytocin
receptor genotype in young adults with high-functioning
autism: a 24-week randomized clinical trial
H Kosaka1,2,3, Y Okamoto1,3, T Munesue4, H Yamasue5, K Inohara2,6, T Fujioka2, T Anme7, M Orisaka8, M Ishitobi2,9, M Jung1,3,
TX Fujisawa1,3, S Tanaka1, S Arai1,3, M Asano1,2,3, DN Saito1,3,10, N Sadato11, A Tomoda1,3, M Omori12, M Sato1,3,13,14, H Okazawa1,3,10,
H Higashida4 and Y Wada1,2,3
Recent studies have suggested that long-term oxytocin administration can alleviate the symptoms of autism spectrum disorder
(ASD); however, factors inﬂuencing its efﬁcacy are still unclear. We conducted a single-center phase 2, pilot, randomized, double-
blind, placebo-controlled, parallel-group, clinical trial in young adults with high-functioning ASD, to determine whether oxytocin
dosage and genetic background of the oxytocin receptor affects oxytocin efﬁcacy. This trial consisted of double-blind (12 weeks),
open-label (12 weeks) and follow-up phases (8 weeks). To examine dose dependency, 60 participants were randomly assigned to
high-dose (32 IU per day) or low-dose intranasal oxytocin (16 IU per day), or placebo groups during the double-blind phase. Next,
we measured single-nucleotide polymorphisms (SNPs) in the oxytocin receptor gene (OXTR). In the intention-to-treat population, no
outcomes were improved after oxytocin administration. However, in male participants, Clinical Global Impression-Improvement
(CGI-I) scores in the high-dose group, but not the low-dose group, were signiﬁcantly higher than in the placebo group. Furthermore,
we examined whether oxytocin efﬁcacy, reﬂected in the CGI-I scores, is inﬂuenced by estimated daily dosage and OXTR
polymorphisms in male participants. We found that 421 IU per day oxytocin was more effective than ⩽ 21 IU per day, and that a
SNP in OXTR (rs6791619) predicted CGI-I scores for ⩽ 21 IU per day oxytocin treatment. No severe adverse events occurred. These
results suggest that efﬁcacy of long-term oxytocin administration in young men with high-functioning ASD depends on the
oxytocin dosage and genetic background of the oxytocin receptor, which contributes to the effectiveness of oxytocin treatment
of ASD.
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INTRODUCTION
Autism spectrum disorder (ASD) is characterized by persistent
deﬁcits in social communication and social interaction across
multiple contexts and restricted, repetitive patterns of behavior,
interests, or activities.1 Although no pharmacologic treatments
exist for the core symptoms of ASD, recent studies have proposed
that intranasal oxytocin administration may be effective.2,3
Recent randomized controlled trials (RCTs) reported positive
effects of long-term oxytocin administration in adults with ASD,4–6
although pediatric efﬁcacy remains controversial.7–9 Anagnostou
et al.4 found that performance on the Reading the Mind in the
Eyes Task (RMET) and Quality of Life Questionnaire improved after
6-week administration of 48 IU per day of oxytocin in adults with
ASD.4 Watanabe et al.5 found that 6-week administration of 48 IU
per day oxytocin improves Autism Diagnostic Observation
Schedule reciprocity scores and brain activity in adults with
ASD.5 In male adolescents and adults with ASD and comorbid
intellectual disabilities, reciprocal social interactions observed
during play sessions or in daily life signiﬁcantly increased after
8-week administration of 16 IU per day.6 These ﬁndings suggest
that long-term oxytocin administration can alleviate core symp-
toms in adults with ASD.
However, several issues need to be resolved before clinically
using oxytocin treatment for adults with ASD.3,10,11 For instance, it
has been proposed that the efﬁcacy of oxytocin administration
depends on dosage.10,12,13 Previous animal14,15 and human studies
on diseases other than ASD16–18 have shown dose-dependent
oxytocin efﬁcacy. A clinical study with divergent single-dose
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oxytocin administration in patients with schizophrenia showed
that 20 IU oxytocin, but not 10 IU oxytocin, ameliorated emotion
recognition deﬁcits in a polydipsic group.18 However, as the effect
of oxytocin administration differs between schizophrenia and
ASD,19 dose dependency of oxytocin administration in individuals
with ASD requires investigation. Nevertheless, no trial has
examined the dose-dependent efﬁcacy in individuals with ASD
by manipulating daily dosage.
Furthermore, the genetic background of oxytocin system might
inﬂuence efﬁcacy of oxytocin administration.19,20 Intranasally
administered oxytocin is considered to act through the oxytocin
receptor (OXTR).21,22 As OXTR contains several dozen single-
nucleotide polymorphisms (SNPs), efﬁcacy of long-term adminis-
tration might differ according to OXTR gene polymorphisms. A
single-dose study in healthy volunteers showed that OXTR gene
polymorphisms altered sensitivity to reward-relevant features of
infants and/or their aversive properties20 and that improvement of
neural response associated with social cooperation differs by OXTR
gene polymorphisms.23 Previous studies reported that genetic
alteration of OXTR is associated with ASD occurrence;21,24 there-
fore, association of genetic polymorphisms with responsiveness to
oxytocin might differ between individuals with and without ASD.
Nonetheless, the association between efﬁcacy of long-term
oxytocin administration and SNPs in OXTR among individuals
with ASD remains unclear.
In this trial, to examine whether dosage and OXTR gene
polymorphisms affect efﬁcacy of oxytocin administration, we
performed a phase 2 clinical pilot trial with 12-week intranasal
oxytocin administration in young adults with high-functioning
ASD. We set two different dosage group (32 and 16 IU per day)
and measured SNPs in OXTR, to examine whether estimated daily
dosage amount and SNPs in OXTR predict improvement of
outcomes.
MATERIALS AND METHODS
Participants
We recruited participants from the University of Fukui Hospital, Kanazawa
University Hospital and a few nearby clinics specializing in ASD treatment.
Eligible participants were young male and female adults over 15 years of
age diagnosed with autistic disorder or pervasive developmental disorder
not otherwise speciﬁed as deﬁned by the Diagnostic and Statistical Manual
of Mental Disorders (DSM-IV-TR).25 Two psychiatrists (HK and TM)
conﬁrmed the diagnosis using the Diagnostic Interview for Social and
Communication Disorders.26 We excluded participants with a history of
major medical or neurological illnesses (that is, epilepsy, signiﬁcant head
trauma, a lifetime history of alcohol or drug dependence), those with
syndromic forms of autism (for example, Rett syndrome and tuberous
sclerosis), intellectual disabilities or other severe neuropsychiatric diseases
(for example, schizophrenia, anxiety and mood disorders) and pregnant
women. This clinical trial was approved by the institutional review board of
the University of Fukui, Japan, and was conducted in accordance with the
Declaration of Helsinki and the Ethical Guidelines for Clinical Studies of the
Ministry of Health, Labour and Welfare of Japan. Written informed consent
was obtained from each participant and parents if the participant was
under 20 years old, after a complete explanation of the trial. For female
participants, we obtained informed consent regarding the need for
contraception and risks of long-term oxytocin administration.
Procedure
Between March 2011 and March 2014, we conducted a single-center phase
2, pilot, randomized, double-blind, placebo-controlled, parallel-group,
clinical trial at the Department of Neuropsychiatry of University of Fukui
Hospital, Japan (UMIN000005211). The trial duration was 32 weeks,
including a 12-week double-blind phase, 12-week open-label phase and
8-week follow-up phase. Dose-dependent efﬁcacy of oxytocin administra-
tion was assessed in the double-blind phase, and safety was monitored in
all phases. Our open-label study showed that Clinical Global Impression-
Improvement (CGI-I) score gradually improved over 6 months.27 Therefore,
we set a longer evaluation period (12 weeks) than that in the previous
RCT4–9 to increase the efﬁcacy. Participants were randomly assigned (1:1:1)
to high-dose oxytocin, low-dose oxytocin and placebo groups during the
double-blind phase. We recruited 20 participants with ASD for each group
regardless of sex. Therefore, a total of 60 individuals with ASD in three
groups participated in this pilot trial. The randomization schedule was
generated by an unmasked statistician not involved in conducting the trial
and data analysis. Randomization was centralized, using a computer-
generated list with random block sizes of six. Participants, their family and
staff were masked to the treatment, and the allocation sequence was not
disclosed until the open-label phase for all the participants was completed.
During the double-blind phase, participants received 32 IU per day (high-
dose group) or 16 IU per day oxytocin (low-dose group), or placebo, in the
form of an intranasal spray. The active drug, Syntocinon spray (Novartis,
Basel, Switzerland), was transferred from the original bottle to a sterile
nasal spray bottle (Oono, Tokyo, Japan). In the open-label phase, all
participants received the same oxytocin dose (32 IU per day). To control
the usage of the spray, we provided detailed instructions on how to use
the spray and conﬁrmed the participant’s usage at every visit. Each
participant visited the hospital every 4 weeks during the trial.
Efﬁcacy and safety assessments
The primary outcomes were the CGI28 and Interaction Rating Scale Advanced
(IRSA)29 scores. The CGI-Severity (CGI-S), which evaluates ASD severity on a 7-
point scale (from 1 ‘normal, not at all ill’ to 7 ‘extremely ill’), was assessed by
an expert psychiatrist (HK) at weeks 0, 12 and 24. The CGI-I, which evaluates
the efﬁcacy of oxytocin administration from week 0 on a 7-point scale (from
1 ‘very much improved’ to 7 ‘very much worse’), was assessed by the same
psychiatrist at weeks 12 and 24. To rate the CGI, the psychiatrist compre-
hensively assessed the participants’ ASD core symptoms and comorbid
symptoms in daily life including social behaviors at episodic event, based on
total clinical experience. Videotaped interactions between each participant
and the psychiatrist at weeks 0, 12 and 24 were assessed using the IRSA,
which is designed to evaluate various communicative function such as
assertiveness or responsiveness in adult–adult interactions.29
Oxytocin administration improves various psychiatric symptoms such as
depression and anxiety, as well as social-communicative dysfunction.30
Therefore, we measured various psychiatric symptoms at weeks 0, 12 and
24 as a secondary outcome using self-report questionnaires of the Zung
Self-rating Depression Scale, state anxiety scale of the State-Trait Anxiety
Inventory, 20-item Toronto Alexithymia Scale and a parent-report
questionnaire of the Aberrant Behavior Checklist.
For a subset of participants, we also measured gaze pattern using an
eye-tracking system and brain activity using resting-state functional MRI at
weeks 0 and 12 because changes of gaze behavior and brain function
might result in improvement of core symptom or comorbidities
(Supplementary Information).
Safety and tolerability were assessed by adverse events and vital signs.
We measured body weight, body temperature, blood pressure and pulse
rate at every visit. Blood examination including blood count, renal and liver
function, thyroid and sex hormone levels (plasma testosterone, estradiol,
progesterone, luteinizing hormones and follicle stimulating hormones),
and plasma oxytocin level were evaluated at weeks 0, 12 and 24. Plasma
oxytocin levels were quantiﬁed using a commercial oxytocin ELISA kit
without extraction (Enzo Life Sciences, Farmingdale, NY, USA).31 Speciﬁ-
cally, we focused on the safety of female participants by having a
gynecologist (MOr) monitor their sex hormone levels, menstrual cycle, and
uterine peristalsis activity using cine MRI32 at weeks 0 and 24.
The acute effects of intranasal oxytocin are reported to persist until 60–
80 min post-administration.33,34 Therefore, we evaluated all outcomes
43 h after oxytocin administration in order to study the long-term rather
than acute treatment effects of oxytocin.
Single-nucleotide polymorphism of OXTR
To determine whether genetic disposition alters the efﬁcacy of oxytocin
administration, we identiﬁed SNPs in the OXTR (HGNC:8529) gene for each
participant. We selected 24 SNPs based on the genotype data in the
Japanese population from the HapMap Project35,36 and previous studies
examining their association with ASD21,24,37 (Supplementary Table 1).
Genomic DNA was extracted from peripheral blood using standard
phenol–chloroform methods with the QIAmp DNA Micro Kit (QIAGEN,
Tokyo, Japan), and all SNPs were genotyped by real-time PCR analysis
using TaqMan genotyping platform and StepOnePlus (Applied Biosystems,
Foster City, CA, USA).
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Statistical analyses
We conducted intention-to-treat (ITT) analyses including all participants,
and subgroup analyses in only male participants with good adherence
(450%) because sex-based differences in responses to oxytocin admin-
istration have been reported (Table 1, Figure 1).2,38 Statistical analyses were
performed using IBM SPSS version 21 (IBM, Armonk, NY, USA) and R
package ‘PARTY’.39
Initially, we examined oxytocin effects in the high-dose and low-dose
groups during the double-blind phase. Because high-dose, but not low-
dose, oxytocin administration improved the symptoms of schizophrenic
patients,18 we hypothesized that the high-dose group shows prominent
improvement. On the basis of this hypothesis, we utilized two-step analysis
with a gatekeeping strategy40 to control the family-wise type 1 error rate.
In the ﬁrst step, we examined whether the high-dose group showed
signiﬁcant improvement in CGI-I score over the placebo group by
independent t-test (two-sided) at week 12, and two-way analysis of
variance (ANOVA) with groups (high-dose/placebo) and time (weeks 0/12)
for the other outcomes. In the second step, we examined whether low-dose
group shows signiﬁcant improvement over the placebo group, but only for
outcomes that showed signiﬁcant improvement in the ﬁrst step of analysis.
Correction of multiple comparisons was conducted with two-sided α=0.004
(0.05/11, number of primary and secondary outcomes). To understand the
size of this effect, we also evaluated Cohen’s effect size.41
Subsequently, among outcomes that revealed signiﬁcant improvement
by oxytocin administration, we examined whether efﬁcacy is inﬂuenced by
dosage and OXTR gene polymorphisms in the two oxytocin groups. We
Table 1. Participant demographics and baseline characteristics
Placebo group Low-dose oxytocin group High-dose oxytocin group
All
(n= 20)
Male
(n=16)
Females
(n= 4)
All
(n= 20)
Male
(n=18)
Females
(n= 2)
All
(n= 20)
Male
(n= 13)
Females
(n=7)
Diagnosis, n (%)
Autistic disorder 18 (90%) 15 (94%) 3 (75%) 17 (85%) 15 (83%) 2 (100%) 19 (95%) 13 (100%) 6 (86%)
PDD-NOS 2 (10%) 1 (6%) 1 (25%) 3 (15%) 3 (17%) 0 (0%) 1 (5%) 0 (0%) 1 (14%)
Age (years), mean (s.d.) 24.9 (6.0) 25.3 (6.0) 23.3 (6.6) 23.1 (6.2) 22.9 (6.4) 24.5 (3.5) 24.8 (8.6) 27.8 (9.1) 19.0 (2.3)
Full-scale IQ, mean (s.d.) 98.5 (17.0) 100.8 (17.5) 90.3 (8.1) 99.2 (12.0) 99.9 (12.2) 93.5 (12.0) 102.2 (12.2) 103.9 (13.4) 99.0 (9.9)
AQ, mean (s.d.) 33.7 (5.8) 32.4 (5.6) 39.0 (2.9) 32.0 (5.2) 32.1 (5.4) 31.0 (2.8) 32.9 (5.2) 32.8 (6.0) 33.1 (3.6)
Number of participants
that received psychotropic
medications, n (%)
4 (20%) 2 (13%) 2 (50%) 5 (25%) 5 (28%) 0 (0%) 10 (50%) 6 (46%) 4 (57%)
Abbreviations: AQ, Autism-Spectrum Quotient; PDD-NOS, pervasive developmental disorder not otherwise speciﬁed (DSM-IV-TR). There was no signiﬁcant
group difference in the ratio of participants with pervasive developmental disorder not otherwise speciﬁed among the three groups (χ2(2)= 1.1, P= 0.57).
62 patients assessed for eligibility (M=48, F=14)
2 ineligible (M=1, F=1)
60 randomized (M=47, F=13)
week   0
week 12
week 32
20 assigned to placebo group
(ITT population; M=16, F=4)
2 discontinued
1 feeling of floating (M=1)
1 poor adherence (M=1)
18 assigned to low-dose oxytocin (16 IU/day) [Week 12-13]
↓
18 assigned to high-dose oxytocin (32 IU/day) [Week 14-23]
18 completed the treatment period (M=14, F=4)
(Subgroup population; M=14)
18 completed the follow-up assessment (M=14, F=4)
week 24
20 assigned to low-dose oxytocin (16 IU/day) group
(ITT population; M=18, F=2)
2 discontinued
1 hypersensitive olfactory stimuli (F=1)
1 poor adherence (M=1)
18 assigned to low-dose oxytocin (16 IU/day) [Week 12-13]
↓
18 assigned to high-dose oxytocin (32 IU/day) [Week 14-23]
18 completed the treatment period (M=17, F=1)
(Subgroup population; M=17)
17 completed the follow-up assessment (M=16, F=1)
1 did not attend the follow-up
assessment (M=1)
20 assigned to high-dose oxytocin (32 IU/day) group
(ITT population; M=13, F=7)
1 discontinued
1 poor adherence (M=1)
19 assigned to low-dose oxytocin (16 IU/day) [Week 12-13]
↓
19 assigned to high-dose oxytocin (32 IU/day) [Week 14-23]
19 completed the treatment period (M=12, F=7)
(Subgroup population; M=12)
18 completed the follow-up assessment (M=12, F=6)
1 did not attend the follow-up
assessment (F=1)
Figure 1. Trial proﬁle. ITT population: intention-to-treat population, which included all study participants; Subgroup population: male
participants with good adherence (450%). F, female participants; ITT, intention-to-treat; M, male participants.
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utilized random forest regression with conditional inference trees
(CTree),42,43 which is a type of machine learning that is widely used.
Random forests are a recursive partitioning method particularly well-suited
to small n large p problems.44 In order to precisely evaluate dosage
amount, the estimated daily oxytocin dosage was calculated by averaging
the total residual quantity of the entire spray bottle for the 84-day double-
blind period for each participant. Furthermore, within the 24 SNPs, SNPs
which deviated from the Hardy–Weinberg equilibrium in the data set
(Po0.05) or had minor-allele frequencies below 5% in the Japanese
population, were excluded from the analysis. We set the estimated daily
oxytocin dosage and genotype of each SNP scored 0, 1 or 2 as predictor
values, and outcome was set as the dependent value.
Table 2. Summary of primary and secondary outcomes in the ITT population and subgroup population in male participants with good adherence
ITT population Subgroup population (male participants with good adherence)
Placebo
group
(n=20)
Low-dose
oxytocin group
(n= 20)
High-dose
oxytocin group
(n= 20)
ANOVA
interaction
P-value (n= 60)
Placebo
group
(n= 14)
Low-dose
oxytocin group
(n=17)
High-dose
oxytocin group
(n=12)
ANOVA
interaction
P-value (n= 43)
Primary outcome
Clinical Global Impression-Severity scale (CGI-S), mean (s.d.)
week 0 6.0 (1.0) 5.8 (0.9) 5.9 (0.8) 5.8 (1.1) 5.9 (0.9) 5.8 (0.8)
week 12 5.4 (1.1) 5.3 (0.9) 5.3 (1.3) 0.94 5.5 (1.2) 5.3 (1.0) 4.8 (1.2) 0.02
week 24 5.0 (1.3) 4.8 (1.0) 5.1 (1.4) 5.2 (1.3) 4.7 (1.0) 4.5 (1.1)
Clinical Global Impression-Improvement scale (CGI-I),a mean (s.d.)
week 12 3.1 (1.1) 2.9 (1.2) 2.6 (1.2) 0.18 3.4 (0.9) 2.8 (1.2) 2.1 (1.0) 0.0011b
week 24 2.7 (1.2) 2.2 (1.1) 2.3 (1.4) 2.9 (1.0) 1.9 (1.0) 1.6 (0.8)
Interaction Rating Scale Advanced (IRSA), mean (s.d.)
week 0 256.0 (47.3) 262.4 (42.7) 272.6 (40.8) 251.3 (46.0) 259.8 (44.4) 283.4 (32.0)
week 12 265.4 (55.3) 276.2 (44.2) 277.1 (50.4) 0.64 266.7 (43.4) 273.5 (46.0) 292.7 (37.0) 0.37
week 24 275.1 (49.6) 281.4 (46.0) 281.1 (40.6) 261.6 (46.4) 280.6 (47.4) 288.0 (35.5)
Secondary outcome
Aberrant Behavior Checklist I: Irritability/Agitation, mean (s.d.)
week 0 10.7 (12.4) 8.8 (8.9) 4.7 (4.8) 6.3 (7.5) 9.3 (9.0) 3.4 (3.5)
week 12 7.4 (9.5) 5.0 (5.9) 2.1 (4.5) 0.88 6.5 (9.6) 5.3 (6.0) 0.2 (0.7) 0.12
week 24 7.8 (10.9) 3.2 (4.8) 2.0 (4.3) 7.4 (10.7) 3.3 (4.9) 0.3 (0.7)
Aberrant Behavior Checklist II: Lethargy/Social Withdrawal, mean (s.d.)
week 0 13.3 (9.1) 19.5 (11.8) 16.8 (10.7) 11.3 (8.7) 20.8 (11.0) 17.7 (12.2)
week 12 9.4 (10.5) 10.4 (9.4) 10.2 (10.9) 0.29 9.5 (11.2) 11.1 (9.3) 9.6 (12.1) 0.20
week 24 10.9 (12.7) 6.2 (6.2) 7.4 (8.1) 11.6 (13.7) 6.6 (6.2) 5.6 (5·9)
Aberrant Behavior Checklist III: Stereotypic Behavior, mean (s.d.)
week 0 3.1 (3.0) 4.0 (4.9) 2.5 (2.3) 3.0 (3.0) 4.3 (4.9) 2.8 (2.7)
week 12 3.6 (4.4) 1.8 (3.2) 1.5 (2.3) 0.07 4.2 (4.7) 1.9 (3.3) 1.3 (1.7) 0.07
week 24 3.6 (4.0) 1.4 (2.9) 1.3 (2.6) 4.2 (4.2) 1.5 (3.0) 0.9 (1.5)
Aberrant Behavior Checklist IV: Hyperactivity/Noncompliance, mean (s.d.)
week 0 9.0 (8.2) 8.3 (8.1) 4.9 (5.5) 6.8 (7.2) 8.9 (8.1) 4.7 (5.5)
week 12 6.2 (8.3) 3.7 (5.2) 2.6 (5.6) 0.92 5.9 (8.9) 3.9 (5.2) 1.3 (3.0) 0.40
week 24 7.3 (10.4) 2.8 (4.3) 2.4 (5.4) 7.4 (11.0) 2.9 (4.3) 0.8 (1.8)
Aberrant Behavior Checklist V: Inappropriate Speech, mean (s.d.)
week 0 3.1 (3.6) 1.6 (2.6) 1.2 (2.1) 2.5 (3.1) 1.7 (2.7) 0.3 (0.5)
week 12 2.3 (2.8) 1.1 (2.4) 0.6 (1.5) 0.85 2.3 (3.0) 1.2 (2.5) 0.2 (0.7) 0.89
week 24 3.0 (3.5) 0.8 (1.9) 0.7 (1.3) 3.1 (3.6) 0.8 (1.9) 0.1 (0.4)
Zung Self-Rating Depression Scale, mean (s.d.)
week 0 48.3 (8.8) 49.0 (8.1) 50.1 (9.0) 47.8 (7.1) 48.8 (8.3) 47.5 (10.9)
week 12 48.4 (8.0) 47.4 (10.6) 47.2 (9.8) 0.24 48.2 (8.5) 46.8 (10.6) 44.5 (10.6) 0.24
week 24 47.5 (8.2) 44.6 (11.0) 46.9 (10.6) 47.2 (8.1) 44.1 (11.2) 44.6 (11.0)
State Anxiety Scale of State-Trait Anxiety Inventory, mean (s.d.)
week 0 53.0 (8.9) 52.0 (10.2) 52.0 (12.7) 51.7 (8.0) 52.2 (10.5) 47.9 (14.2)
week 12 49.8 (10.1) 50.2 (13.4) 48.3 (13.6) 0.95 47.9 (10.1) 49.9 (13.7) 44.5 (13.9) 0.94
week 24 52.0 (12.7) 48.4 (11.7) 49.5 (13.0) 49.0 (12.2) 47.9 (11.8) 45.6 (12.4)
The 20-item Toronto Alexithymia Scale, mean (s.d.)
week 0 62.4 (6.9) 58.1 (10.5) 61.4 (14.4) 61.3 (7.0) 57.9 (10.8) 61.2 (16.4)
week 12 60.5 (13.1) 58.2 (13.0) 57.2 (14.8) 0.47 56.8 (10.5) 58.7 (13.3) 56.7 (18.1) 0.99
week 24 60.2 (13.8) 56.0 (17.0) 60.6 (13.9) 56.4 (11.3) 55.8 (17.6) 59.3 (18.0)
Monitoring item
Plasma oxytocin concentration (pg ml− 1), mean (s.d.)
week 0 226.6 (125.7) 251.2 (169.0) 285.0 (198.3) 208.6 (96.1) 262.9 (173.4) 256.4 (195.6)
week 12 231.7 (104.9) 221.7 (109.5) 265.6 (176.4) 0.61 216.3 (106·0) 228.9 (112.6) 220.6 (124.1) 0.46
week 24 231.6 (128.1) 213.2 (142.0) 237.7 (167.1) 192.5 (74.9) 230.7 (136.7) 205.2 (127.5)
Abbreviations: ANOVA, analysis of variance; ITT, intention-to-treat. ANOVA indicates a two-way ANOVA of each outcome with group (high-dose oxytocin group
and placebo group) and time (weeks 0 and 12) as factors in the double-blind phase, unless otherwise indicated. aFor only CGI-I, t-test was performed for the
high-dose oxytocin group and placebo groups at week 12 (two-sided). bPo0.004 (0.05/11).
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RESULTS
Participants and trial proﬁle
We enrolled 62 eligible Japanese participants between 18 March
2011 and 24 September 2013, and two of them were excluded for
not meeting diagnosis criteria (Figure 1). Therefore, 60 participants
(47 males and 13 females, aged 15–39 years (mean 24.2 years),
full-scale IQ 76–133 (mean 100.0)) were randomly allocated to
three groups (Table 1). Twenty-two participants (36.7%) had
received psychotropic medications because of comorbid symp-
toms, with stable doses over a month prior to randomization.
During the double-blind phase, two participants discontinued
the trial, and three participants with poor adherence (⩽50%),
conﬁrmed by self-report and residual quantity of the spray bottle,
were excluded from the subgroup analysis (Figure 1). Therefore,
55 of 60 participants (91.7%) continued the intranasal spray
administration throughout the trial period. We analyzed the 60
and 43 participants for ITT population and subgroup population
(male participants with good adherence), respectively.
Outcomes and safety
Initially, we examined oxytocin effects in high-dose and low-dose
groups during the double-blind phase. In the ﬁrst step of analysis
(high-dose vs placebo group), t-test did not reveal a signiﬁcant
difference in CGI-I score and two-way ANOVA on the other
outcomes revealed no signiﬁcant interaction between group and
time in the ITT population (Table 2). When we analyzed the
subgroup of male participants, t-test revealed signiﬁcant improve-
ment in CGI-I score in the high-dose oxytocin group over the
placebo group (t(24) = 3.714, P= 0.001, two-sided; Cohen’s
d= 1.52) with high post hoc power (0.944). By contrast, two-way
ANOVA of the other outcomes with group and time as factors
revealed no signiﬁcant interaction in the subgroup population
(Table 2). In the second step of analysis (low-dose vs placebo
group), t-test did not reveal a signiﬁcant difference in CGI-I score
between the two groups (P= 0.08, two-sided). Collectively, these
results indicate that male participants in the high-dose group, but
not the low-dose group, showed signiﬁcant improvement in CGI-I
score, suggesting that dose-dependent efﬁcacy exist. There was a
signiﬁcant correlation between the CGI-I score at week 12 and the
estimated daily oxytocin dosage (n= 43, r=− 0.512, Po0.001).
Subsequently, we examined whether efﬁcacy was inﬂuenced by
dosage and OXTR gene polymorphisms by analyzing CGI-I scores
of the subgroup population at week 12 in both high-dose (12
males) and low-dose groups (16 males, excluding a male who
refused to provide a blood sample). Estimated daily oxytocin
dosages were 28.8 ± 4.5 (18.9–32.0) and 13.5 ± 1.4 IU (10.4–15.2)
for the high-dose and low-dose groups, respectively. We excluded
ﬁve SNPs (rs2270465, rs2301261, rs2268494, rs1042778 and
rs237884) based on the exclusion criteria, and the remaining 19
SNPs were subjected to random forest regression analysis
(Supplementary Table 1). As shown at the top of the tree in
Figure 2, we estimated the daily oxytocin dosage as a superior
predictor of CGI-I score compared with 19 SNPs in OXTR (Figure 2;
C= 6.59, Po0.001). As a second candidate, rs6791619 was also
signiﬁcantly predictive under lower-dose oxytocin treatment
(⩽21 IU; Figure 2; C= 5.42, Po0.001). Other SNPs were not
signiﬁcantly predictive of CGI-I score improvement. Collectively,
participants receiving higher-dose (421 IU) oxytocin showed
stronger improvement of CGI-I score. Furthermore, when the
dosage was lower (⩽21 IU), participants with a T-allele at
rs6791619 showed stronger improvement.
We further examined whether gaze abnormality and altered
brain function are affected by oxytocin administration for a subset
of participants (Supplementary Information). We found that long-
term administration of high-dose oxytocin has a tendency to
increase gaze ﬁxation on regions of social salience such as the eye
region of the face and biological motion, with large effect size. In
resting-state functional MRI analysis, we could not compare
activation between high-dose and placebo groups because of the
small number of participants in the high-dose group (n= 1).
Across the clinical trial, no severe adverse events or abnormal
physiological changes were observed (Table 3). Female partici-
pants did not complain about menstrual disorders and galactor-
rhea, and a gynecologist conﬁrmed that there was no abnormality
in sex hormone levels, menstrual cycle and uterine peristaltic
activity. Two-way ANOVA on plasma oxytocin level revealed no
main effects of group and time or interaction between group and
time (P40.05; Table 2).
DISCUSSION
In the pilot clinical trial, we conﬁrmed that high-dose oxytocin
administration for 12 weeks alleviates symptoms in male young
adults with ASD with no severe adverse event. Furthermore, we
provide novel evidence that the efﬁcacy of oxytocin administra-
tion in male participants can be predicted by dosage and a SNP in
OXTR (rs6791619).
Efﬁcacy of long-term oxytocin administration
In this trial, signiﬁcant improvement was observed in CGI-I score
but not in other outcomes for male participants in the high-dose
group. To assess the CGI score, we comprehensively assessed the
participant’s ASD core symptoms and comorbid symptoms in daily
life including social behaviors at episodic event, and showed that
oxytocin administration can alleviate comprehensive symptoms.
Previous ﬁndings also suggested that social-communicative skills,
that is, Autism Diagnostic Observation Schedule reciprocity score5
and social interactions during the play sessions and daily life,6
were improved by long-term oxytocin administration;5,6 however,
we could not observe signiﬁcant improvement in IRSA, which
helps evaluate various social-communicate behaviors during
mean = 3.4 (0.7) mean = 2.6 (1.2) mean = 1.7 (0.7)
Figure 2. Assessment of the relative signiﬁcance of variables (the
estimated daily oxytocin dosage and 19 SNPs) for improvement of
symptoms using conditional regression trees in the program
package ‘PARTY’ (implemented in R) for the subgroup population.
The thick line shows the median values of the CGI-I score and the
vertical dashed line shows the range. The lowest data are mean (s.d.)
of the CGI-I score at week 12. CGI-I, Clinical Global Impression-
Improvement; SNP, single-nucleotide polymorphism.
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medical interview. The inconsistent results might be because of
difference in the assessment procedure. Autism Diagnostic
Observation Schedule and social interactions measured by
Munesue et al.6 were assessed by the evaluator after interacting
with the participants. In contrast, the IRSA was assessed by
videotaped interactions by the evaluator without interacting with
the participants. Previous studies have found that oxytocin
administration improves eye contact during naturalistic social
interaction.5,45 We also observed an increasing tendency to look at
the eye-region for some face movies (that is, still face, blinking)
with large effect size (Supplementary Information) in the high-
dose oxytocin group. Such changes in gaze-behaviors are easier to
detect by the person interacting with the participants than by a
third person. Therefore, we could not detect changes in social-
communicative behaviors by IRSA possibly because the assess-
ment procedure used a videotaped interaction, in contrast to our
ﬁndings of CGI-I score and those of previous trials.5,6 Other than
comprehensive symptom and social-communicative behaviors,
we failed to ﬁnd signiﬁcant improvement of secondary outcomes
assessing stereotypic behavior and comorbidity including anxiety
and depressive state, which was consistent with the results of
previous studies.3–9 Therefore, long-term administration of oxyto-
cin might not be effective for improving stereotypic and repetitive
behavior, and comorbid symptoms. Overall, our results show that
comprehensive symptoms of males with ASD improved after
administration of 32 IU oxytocin for 12 weeks.
Efﬁcacy of oxytocin administration is predicted by dosage and
OXTR gene polymorphisms
In the trial, we provided novel evidence that administration of
421 IU per day oxytocin for 12 weeks is more effective than
⩽ 21 IU per day in treating comprehensive symptoms as measured
by CGI-I score (Figure 2), which is consistent with ﬁndings of
previous clinical trial in patients with schizophrenia.18 It is
estimated that only a small amount of intranasally administered
oxytocin reaches the brain.33,34,46,47 For instance, a recent study
showed that single-dose intranasal administration of 24 IU
oxytocin increases the cerebrospinal ﬂuid oxytocin level 1.5-fold
in volunteers without ASD.34 Leng and Ludwig48 reported that a
maximum of 0.005% of intranasally injected oxytocin reaches the
cerebrospinal ﬂuid within 1 h.48 This is likely because of the limited
number of routes to reach the brain, such as blood-brain barrier
and extraneuronal/perineuronal routes along the trigeminal or
olfactory nerves.10,49–53 Oxytocin levels in individuals with ASD
are lower than those in typically developing individuals.54,55
Therefore, sufﬁcient amount of oxytocin is necessary to actually
reach the brain in individuals with ASD to compensate for the
lower oxytocin level.
In addition to dosage, we found that participants with the
T-allele at rs6791619 showed stronger improvement of CGI-I score
when dosage was lower (⩽21 IU per day). Although a recent meta-
analysis revealed that rs6791619 is not solely associated with ASD
occurrence,21 the SNP is considered a part of haplotype associated
Table 3. Adverse events
During double-blind phase
(12 weeks from week 0 to 11)
During open-label and follow-up phase
(20 weeks from week 12 to 31)
Placebo group
(n= 20) (M= 16,
F= 4)
Low-dose oxytocin
group (n= 20)
(M= 18, F= 2)
High-dose
oxytocin group
(n= 20)
(M= 13, F= 7)
Placebo group
(n= 18)
(M= 14, F= 4)
Low-dose oxytocin
group (n= 18)
(M= 17, F= 1)
High-dose
oxytocin group
(n= 19)
(M= 12, F= 7)
Total adverse events, n (%) 6 (30) 5 (25) 3 (15) 5 (28) 1 (6) 7 (33)
Patients reporting one or more
adverse events, n (%)
4 (20) 4 (20) 3 (15) 5 (28) 1 (6) 5 (26)
Speciﬁc adverse events, n (%)
Somnolence 1 (5) 1 (5) 1 (5) 1 (6) 1 (6) 2 (11)
Feeling of ﬂoating 1 (5) 0 0 0 0 1 (5)
Palpitation 1 (5) 0 0 0 0 0
Nausea 0 0 0 1 (6) 0 0
Hypersensitive olfactory
stimuli
0 1 (5) 0 0 0 0
Itching of the nose 1 (5) 0 0 0 0 0
Heat sensation of the glabella 0 1 (5) 0 0 0 0
Acoustic hyperesthesia 0 0 0 0 0 0
Abnormal sensation of lower
limb
0 0 0 0 0 1 (5)
Decreased activity 0 0 1 (5) 0 0 1 (5)
Worsened obsessive behavior 1 (5) 1 (5) 0 1 (5) 0 1 (5)
Irritability 1 (5) 0 0 1 (5) 0 0
Hyperthymia 0 0 0 0 0 1 (5)
Excessive contact with
acquaintances
0 1 (5) 1 (5) 0 0 0
Playful attitude 0 0 0 1 (6) 0 0
Speciﬁc adverse events (female participants)
Abnormal change of sex
hormone level
0 0 0 0 0 0
Menstrual problem 0 0 0 0 0 0
Galactorrhea 0 0 0 0 0 0
Abnormal uterine peristalsis 0 0 0 0 0 0
Abbreviations: ANOVA, analysis of variance; F, female participants; M, male participants; NA, not available. During the double-blind phase, one-way ANOVA
showed no signiﬁcant differences in the number of patients who experienced one or more adverse events among the groups (P40.05).
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with impairment of core ASD symptoms.37 Wermter et al.37 found
that 11 carriers of the T–G–T–T haplotype at rs237851–rs6791619–
rs53576–rs237884 have more impairment than 89 noncarriers in
social interaction and communication domains of the Autism
Diagnostic Interview-Revised56 in individuals with ASD. There is a
possibility that participants with T-allele at rs6791619 that showed
stronger improvement in our clinical trial might be associated with
the non-severe symptoms group reported by Wermter et al.37
However, since only one participant had T–G–T–T haplotype at
rs237851–rs6791619–rs53576–rs237884 in the present trial, we
cannot examine whether the efﬁcacy was different between
carriers of T–G–T–T haplotype at rs237851–rs6791619–rs53576–
rs237884. In other words, 7 out of 8 participants (Figure 2), who
did not have T alleles (that is, CC) at rs6791619, and who were not
carriers of T–G–T–T haplotype at rs237851–rs6791619–rs53576–
rs237884, showed lower efﬁcacy of oxytocin administration.
Therefore, we speculate a possibility that a SNP of rs6791619,
rather than the haplotype at rs237851–rs6791619–rs53576–
rs237884, might modulate responsibility of long-term oxytocin
administration for males with ASD.
Collectively, we demonstrated that administration of 421 IU
per day intranasal oxytocin is effective to alleviate comprehensive
symptoms of ASD in males. Furthermore, when the dosage was
⩽ 21 IU per day, a SNP in OXTR (rs6791619) is associated with the
efﬁcacy of oxytocin administration. These ﬁndings should navigate
future RCTs and contribute to establishing oxytocin administration
as medical treatment in individuals with ASD.
Safety
In the present trial, we did not observe any severe adverse events
during a 12-week period of oxytocin administration. As this is the
longest duration RCT of oxytocin in ASD to date (that is, previous
RCTs lasted from 5 to 8 weeks), our data conﬁrm the safety of
long-term oxytocin treatment for use in future trials. Furthermore,
oxytocin did not produce any abnormalities in the sex hormones,
menstrual cycles or uterine peristaltic activity of the 13 female
participants with ASD included in this RCT. Although oxytocin is
known to induce uterine contractions,57 no other RCTs have
evaluated the hormonal actions of long-term oxytocin adminis-
tration in female participants. Thus, our results provide new
evidence that long-term administration of oxytocin at a dose
⩽ 32 IU per day for 12 weeks does not lead to hormone-related
abnormalities in non-pregnant females, which should encourage
further RCTs on female participants with ASD.
Limitation and further study
There are three limitations of the present pilot trial. First, although
we provide the novel ﬁnding of dose-dependent efﬁcacy with
⩽ 32 IU per day oxytocin and longer treatment duration than
previous RCTs, we did not conﬁrm the efﬁcacy of higher dosage
and time dependency in the double-blind phase. A rodent study
showed negative ﬁnding such as deﬁcit in partner preference
behavior after long-term development treatment with lower doses
of oxytocin.58 Therefore, further studies examining safety and
efﬁcacy at various dosages and administration periods are
necessary. Second, because of smaller number of participants,
we could not sufﬁciently examine the association between
OXTR gene polymorphisms or sex and oxytocin efﬁcacy. Further
studies with larger sample size are warranted. Third, we found
no signiﬁcant changes in plasma oxytocin level. Non-extracted
approaches may not have been appropriate as a
methodology.48,59
In conclusion, we showed dose- and genetic-dependent
efﬁcacy of oxytocin administration for comprehensive ASD-
related symptoms in young males with high-functioning ASD.
These ﬁndings are crucial for establishment of a therapeutic
paradigm for oxytocin administration in individuals with ASD.
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